Merrill Lynch Capital Markets Espana SA SV has reportedly bought 21.40 lakh shares or 0.79% stake of Glenmark Pharmaceuticals through the open market route. The shares were purchased on an average price of Rs 518.80 valuing the transaction to Rs 111.52 crore.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
